Linagliptin/pioglitazone

Drug Profile

Linagliptin/pioglitazone

Alternative Names: Pioglitazone/linagliptin

Latest Information Update: 15 May 2015

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules; Thiazolidinediones
  • Mechanism of Action CD26 antigen inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 15 May 2015 Linagliptin/pioglitazone is still in active development for Type-2 diabetes mellitus in USA, United Kingdom, Estonia, Germany, Latvia and Spain
  • 29 Oct 2014 Boehringer Ingelheim and Eli Lilly restructure their diabetes alliance in certain countries
  • 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top